Atty. Dkt. No. 351325-0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SARAGOVI et al.

Title: COMPOUND TARGETED FOR SPECIFIC CELLS WITH

REDUCED SYSTEMIC TOXICITY

TOXICITI

Appl. No.: 10/600623

Filing Date: June 20, 2003

Examiner: Brandon I Fetterolf

Art Unit: 1642

Confirmation 7195

Number:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP \$609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(2) that no item of information contained in this supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the supplemental information disclosure statement was known to any individual designated in 37 CFR §1.5(c) more than three months prior to the filing of the supplemental information disclosure statement.

FEE

Fees in the amount of \$180.00 in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(d) are being paid by credit card via EFS-Web. The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-3431. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-3431.

Respectfully submitted,

Date March 1, 2007

FOLEY & LARDNER LLP Customer Number: 48329 Telephone: (617) 342-4088 Facsimile: (617) 342-4001 James F. Ewing Attorney for Applicant Registration No. 52,875

PTQ/SB/08 (09-08) Approved for use through 03/31/2007. OMB 0651-0031

Under the Pape number.	rwork Reduction Act	of 1995	, no persons are	required to respond to a collection of in	nformation unless it contains a valid OMB control	1
Substitute for form 1448/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 1, 2007 (use as many sheets as necessary)				Complete if Known		
				Application Number	10/600623	
				Filing Date	June 20, 2003	
				First Named Inventor	Uri H. Saragovi	-
				Art Unit	1642	-
				Examiner Name	Brandon J. Fetteroff	
Sheet	1	of	1	Attorney Docket Number	351325-0102	_

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Initials* No.1	No.1	Number-Kind Code ² (Finown)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	-				

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS U.S. Patent Application Peges, Columns, Lines, Filing Date of Examiner Cite Document Name of Petentee or Applicant of Where Relevant Cited Document nitiala* Cited Document Pessages or Relevant No Serial Number-Kind Code² (if MM-DD-YYYY Anown) Figures Appear

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code" Number Kind Code" (if Anown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B-3	EP 0 294 294 B1	05-17-1995	Dalton H. King et al.		_
	B-4	WO 00/33888	06-15-2000	Thomas J. Lobi et al.	1	
				1	T	

Include name of the author (in CAP(TAL LETTERS), title of the article	
Examiner Initials* Cite No. Cite N	

	- Martin Martin Control	
Examiner	Date	

Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www usofs gov or MPEP 901.04. 3 Enter Office that issued the document, by the ben-letter code (NMPO Standard ST S1.4 For Japanese patient documents, the indication the year of the raign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document.

under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark have 8 English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retain a penselt by the public which is to file (and by the USPTO to modestal an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including patients, proparing. and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information of the U.S. Patent and Trademark Office, p. 18 ox 1450, Abstanding, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Abstanding, VA 22313-1450.